What Insurance Does a Life Sciences Company Need at the Seed Stage?

A seed-stage life sciences company needs a minimum viable insurance program: the few lines that real activity demands, and not much more. The common mistakes run in both directions. Founders overbuy on lines that matter later and underbuy on the ones tied to what the company is actually doing now. The goal at seed is to cover real exposure without paying ahead of it, which is the first stage of the arc laid out in how insurance changes at each funding stage.

Start From What the Company Actually Does

The right seed program follows activity, not ambition. The questions that set it are concrete. Is anyone using the product, or has it left your control. Do you handle protected health information or other sensitive data. Have you hired. Do you have a lease, a contract manufacturer, or a clinical site. Each yes turns on a specific line, and the lines a company genuinely needs at seed are usually few. A company still on the bench with no human contact and no data carries far less than one running an early study or holding patient records.

This is why a generic startup bundle often misses the point. It is priced for a generic small business, and a life sciences company’s real early exposures, product, data, or clinical activity, sit outside what the bundle was built to answer.

The Lines That Usually Matter First

For most seed-stage life sciences companies, a small set of lines carries the weight. General liability is the baseline for premises and operations claims. Where there is a physical product and any human use or distribution, product liability becomes the line that matters most, and for a device that exposure can begin before clearance, which is why it should be timed to first human use and first shipment rather than the FDA calendar. Where the company handles health data, cyber written with HIPAA in mind is the early priority rather than an afterthought. Once there are employees, workers compensation is required in most states, and basic employment exposure begins.

What usually does not need to be large yet is the management-liability tower. Directors and officers coverage tends to become a real requirement at the first priced round rather than at formation, unless the company already has outside directors. Buying a heavy D&O program before there is a board or institutional capital is a common overbuy.

Avoid the Two Seed-Stage Errors

The overbuy is paying for limits and lines sized for a company two stages ahead. The underbuy is skipping the one line tied to current activity, most often product liability when a device is already in someone’s hands, or cyber when the company is already holding data. Both errors come from treating insurance as a status symbol or a checkbox rather than a match to exposure. The discipline is to insure what is live now and to revisit at the next round, because the program is meant to change as the company does, the through-line across the full funding-stage arc.

The other seed-stage reality is contracts. A contract manufacturer, a clinical site, an academic partner, or a lease can each require evidence of coverage on its own timeline, and those requirements, not the company’s internal sense of readiness, often dictate when a line has to be in place. Mapping those obligations early keeps a deal from stalling on a missing certificate. The way investor counsel will later read the program is previewed in the Series A diligence framing, and building cleanly at seed makes that review easier.

What to Do Now

List the company’s live activities and the contracts that demand proof of insurance, then place coverage against those and stop there. Resist both the urge to buy the mature program early and the urge to defer the one line your current activity requires. A short call with a broker who places life sciences programs will sort which lines need to bind now and which can wait for the next round.

Before your seed program renews or your raise begins, confirm the coverage matches what the company is actually doing today. A specialty review through Tower Street Insurance can build a seed-stage life sciences program that covers real exposure without paying for the stage you have not reached yet.